MeSH tree: D12.776.377.715.548.114.224.200.829
Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease. Despite advances in treatment, survival rates for high-risk and ...
Jan 23, 2025
0
13
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Jan 3, 2025
0
28
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation factor 15 (GDF-15) can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors.
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center ...
Nov 14, 2024
0
17
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical ...
Nov 1, 2024
0
39
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...
Oct 16, 2024
1
75
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for Immunotherapy, and Bristol Myers Squibb has published the most comprehensive overview to date of ...
Oct 1, 2024
0
71
The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The phase II portion of the NRG-HN005 evaluated two experimental treatment ...
Sep 30, 2024
0
26
Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized Phase II/III trial after patients in the ...
Sep 30, 2024
0
24
For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI), tivozanib has efficacy, according to a study published ...
Sep 20, 2024
0
45
